{"product_id":"diagnosis-and-treatment-of-joint-disease-of-small-animals","title":"Diagnosis And Treatment Of Joint Disease Of Small Animals","description":"\u003cp\u003eDiagnosis And Treatment Of Joint Disease Of Small Animals | File size: 10 MB | Format: PDF | Categories: Animals Books \u0026gt; Small Animals \u0026gt; Diagnosis and treatment of Joint Disease of Small Animals\u003c\/p\u003e\u003cp\u003eDigital veterinary textbook. Instant download after purchase.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSave 24% — Limited time offer!\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eTable of Contents\u003c\/h3\u003e\n\u003cdiv class=\"gvc-locked-preview\"\u003e\n  \u003cdiv class=\"gvc-locked-icon\"\u003e🔒\u003c\/div\u003e\n  \u003ch3\u003eSample Preview\u003c\/h3\u003e\n  \u003cp\u003eThe full PDF is available after purchase. Instant download. Lifetime access. Read on any device.\u003c\/p\u003e\n  \u003cp class=\"gvc-locked-meta\"\u003eTrusted by 4,000+ veterinary professionals worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cul\u003e\n  \u003cli\u003eContents (p.8)\u003c\/li\u003e\n  \u003cli\u003ePreface (p.20)\u003c\/li\u003e\n  \u003cli\u003e1 - Nature and Scope of the Chapter (p.25)\u003c\/li\u003e\n  \u003cli\u003e2 - The Subject Matter of Biomedical Animal Research Ethics (p.25)\u003c\/li\u003e\n  \u003cli\u003e3 - Why Investigators Should Care About Biomedical Animal Research Ethics (p.26)\u003c\/li\u003e\n  \u003cli\u003e4 - Aspects of Animal Use and Care Relevant to Biomedical Animal Research Ethics (p.29)\u003c\/li\u003e\n  \u003cli\u003e5 - Use of Privately Owned Animals in Biomedical Research (p.30)\u003c\/li\u003e\n  \u003cli\u003e6 - The Nature of Basic Animal Research (p.31)\u003c\/li\u003e\n  \u003cli\u003e7 - Why Investigators Play the Key Role in Ensuring the Ethical Conduct of Animal Research Projects (p.33)\u003c\/li\u003e\n  \u003cli\u003e8 - Sources of Guidance for Investigators in Conducting Ethical Research (p.38)\u003c\/li\u003e\n  \u003cli\u003e9 - Developing Useful Ethical Guidelines (p.40)\u003c\/li\u003e\n  \u003cli\u003e10 - Fundamental Principles of biomedical animal Research Ethics (p.41)\u003c\/li\u003e\n  \u003cli\u003e11 - Practical Ethical Guidelines for Investigators (p.58)\u003c\/li\u003e\n  \u003cli\u003e12 - Some Current Difficult Issues in Animal Research Ethics (p.60)\u003c\/li\u003e\n  \u003cli\u003e13 - General Suggestions for Investigators (p.62)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.63)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.68)\u003c\/li\u003e\n  \u003cli\u003e2 - Enrichment and Welfare (p.69)\u003c\/li\u003e\n  \u003cli\u003e3 - Enrichment and Animal Models (p.76)\u003c\/li\u003e\n  \u003cli\u003e4 - Enrichment and Experimental Variability (p.79)\u003c\/li\u003e\n  \u003cli\u003e5 - Implementing an Enrichment Plan (p.79)\u003c\/li\u003e\n  \u003cli\u003e6 - Example of an Enrichment Plan: Black-Tailed Prairie Dogs (Cynomys ludovicianus) (p.82)\u003c\/li\u003e\n  \u003cli\u003e7 - Conclusions (p.83)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.83)\u003c\/li\u003e\n  \u003cli\u003e1 - Animal Models (p.93)\u003c\/li\u003e\n  \u003cli\u003e2 - Why Animal Experimental Studies? (p.93)\u003c\/li\u003e\n  \u003cli\u003e3 - Animal Models in Biomedical Research (p.94)\u003c\/li\u003e\n  \u003cli\u003e4 - Concerns About the Translatability of Findings From Animal Experimental Studies (p.94)\u003c\/li\u003e\n  \u003cli\u003e5 - Translational Research (p.94)\u003c\/li\u003e\n  \u003cli\u003e6 - Choice of Appropriate Animal Model (p.96)\u003c\/li\u003e\n  \u003cli\u003e7 - Where in the Process of Modeling Human Diseases and Developing Putative Therapeutics Have Large Animal Models Been Used? (p.98)\u003c\/li\u003e\n  \u003cli\u003e8 - Which Model Animal Species Are Classified as Large in Scientific Research? (p.99)\u003c\/li\u003e\n  \u003cli\u003e9 - Which Types of (Large) Animal Models Are Available? (p.100)\u003c\/li\u003e\n  \u003cli\u003e10 - Special Aspects in Using Large Farm Animal Models (p.101)\u003c\/li\u003e\n  \u003cli\u003e11 - Experimental Unit (p.102)\u003c\/li\u003e\n  \u003cli\u003e12 - Experiments Using Social Animals Requiring Group Housing (p.104)\u003c\/li\u003e\n  \u003cli\u003e13 - Putative Advantages and Disadvantages of Group Housing (p.105)\u003c\/li\u003e\n  \u003cli\u003e14 - Principles of the 3R—Replacement, Reduction, Refinement (p.105)\u003c\/li\u003e\n  \u003cli\u003e15 - Getting the Most Out of an Animal Experimental Study (p.106)\u003c\/li\u003e\n  \u003cli\u003e16 - Need to Correct for Multiple Comparisons? (p.107)\u003c\/li\u003e\n  \u003cli\u003e17 - Replication Studies (p.107)\u003c\/li\u003e\n  \u003cli\u003e18 - Identification of Possible Confounds (p.108)\u003c\/li\u003e\n  \u003cli\u003e19 - Effects of Obesity on Experimental Results (p.109)\u003c\/li\u003e\n  \u003cli\u003e20 - Testing Under Uniform Conditions in the Laboratory Versus Testing in a Heterogeneous Environment, Such as a Farm (p.110)\u003c\/li\u003e\n  \u003cli\u003e21 - Training and Testing May Act as Environmental Enrichment (p.111)\u003c\/li\u003e\n  \u003cli\u003e22 - Modeling Early Live Events That Affect Subsequent Development (p.111)\u003c\/li\u003e\n  \u003cli\u003e23 - Brain Infarction, Hemorrhage, Traumatic Brain Injury (p.112)\u003c\/li\u003e\n  \u003cli\u003e24 - Aging and Aging-Related Diseases (p.112)\u003c\/li\u003e\n  \u003cli\u003e25 - Transgenic Large Animal Models (p.113)\u003c\/li\u003e\n  \u003cli\u003e26 - Discussion (p.113)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.116)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.124)\u003c\/li\u003e\n  \u003cli\u003e2 - Cataract Types (p.125)\u003c\/li\u003e\n  \u003cli\u003e3 - Age-Related Nuclear Cataract (p.126)\u003c\/li\u003e\n  \u003cli\u003e4 - Diabetic Cortical Cataract (p.126)\u003c\/li\u003e\n  \u003cli\u003e5 - Animal Models of Diabetic Cataract (p.130)\u003c\/li\u003e\n  \u003cli\u003e6 - Assessment of Diabetic Cataract Animal Models (p.133)\u003c\/li\u003e\n  \u003cli\u003e7 - Conclusions (p.133)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.134)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.139)\u003c\/li\u003e\n  \u003cli\u003e2 - Time-Course Progression of MNU-Induced Retinal Degeneration (p.140)\u003c\/li\u003e\n  \u003cli\u003e3 - Retinal Degeneration Caused by MNU in Various Animal Species (p.141)\u003c\/li\u003e\n  \u003cli\u003e4 - Age-Related Photoreceptor Cell Damage and Sensitivity to MNU (p.143)\u003c\/li\u003e\n  \u003cli\u003e5 - Photoreceptor Cell Death, Cell Debris Removal, and RPE Cell Migration (p.144)\u003c\/li\u003e\n  \u003cli\u003e6 - Molecular Mechanisms in Photoreceptor Cell Death Caused by MNU (p.147)\u003c\/li\u003e\n  \u003cli\u003e7 - Therapeutic Trials Against MNU-Induced Photoreceptor Apoptosis (p.150)\u003c\/li\u003e\n  \u003cli\u003e8 - Concluding Remarks (p.157)\u003c\/li\u003e\n  \u003cli\u003e9 - Appendix: Special Techniques (p.157)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.160)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.168)\u003c\/li\u003e\n  \u003cli\u003e2 - Myocardial Ischemic Models (p.169)\u003c\/li\u003e\n  \u003cli\u003e3 - Hypertension and Left Ventricular Hypertrophy Models (p.179)\u003c\/li\u003e\n  \u003cli\u003e4 - Heart Failure Models (p.182)\u003c\/li\u003e\n  \u003cli\u003e5 - Models Without Cardiovascular Diseases (p.189)\u003c\/li\u003e\n  \u003cli\u003e6 - Future Directions (p.193)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.193)\u003c\/li\u003e\n  \u003cli\u003e1 - The Heart and Diabetes Mellitus (p.196)\u003c\/li\u003e\n  \u003cli\u003e2 - Methodological Aspects (p.197)\u003c\/li\u003e\n  \u003cli\u003e3 - Experimental Results in the Rat Model of Streptozotocin-Induced Diabetes (p.200)\u003c\/li\u003e\n  \u003cli\u003e4 - Experimental Results in Rat Model of Renal Failure (p.204)\u003c\/li\u003e\n  \u003cli\u003e5 - The Heart and Dysfunctional Sympathetic Innervation (p.211)\u003c\/li\u003e\n  \u003cli\u003e6 - Methods of Chemical Sympathectomy (p.212)\u003c\/li\u003e\n  \u003cli\u003e7 - Experimental Results in the Rat Model of Chemical Sympathectomy (p.212)\u003c\/li\u003e\n  \u003cli\u003e8 - Functional Parameters (p.215)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.220)\u003c\/li\u003e\n  \u003cli\u003e1 - Primate Models (p.227)\u003c\/li\u003e\n  \u003cli\u003e2 - Porcine Models (p.228)\u003c\/li\u003e\n  \u003cli\u003e3 - Rabbit Models (p.229)\u003c\/li\u003e\n  \u003cli\u003e4 - Mouse Models and Atherosclerosis (p.230)\u003c\/li\u003e\n  \u003cli\u003e5 - Concluding Comments (p.236)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.236)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction and Overview (p.242)\u003c\/li\u003e\n  \u003cli\u003e2 - Choosing an Animal Model of MetS (p.243)\u003c\/li\u003e\n  \u003cli\u003e3 - Animal Models of MetS Etiology (p.245)\u003c\/li\u003e\n  \u003cli\u003e4 - Genetic Factors (p.245)\u003c\/li\u003e\n  \u003cli\u003e5 - Environmental Factors (p.253)\u003c\/li\u003e\n  \u003cli\u003e6 - Animal Models of MetS Pathophysiology (p.255)\u003c\/li\u003e\n  \u003cli\u003e7 - Conclusions (p.258)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.258)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.266)\u003c\/li\u003e\n  \u003cli\u003e2 - Type 1 Diabetes (p.267)\u003c\/li\u003e\n  \u003cli\u003e3 - Type 2 Diabetes (p.273)\u003c\/li\u003e\n  \u003cli\u003e4 - Diabetic Complications (p.279)\u003c\/li\u003e\n  \u003cli\u003e5 - Gender, Strain, and Age Effects in Animal Models of Diabetes (p.280)\u003c\/li\u003e\n  \u003cli\u003e6 - Conclusions (p.280)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.280)\u003c\/li\u003e\n  \u003cli\u003e1 - Obesity is a Global Crisis (p.288)\u003c\/li\u003e\n  \u003cli\u003e2 - Obesity: An Unsolved Medical Problem (p.289)\u003c\/li\u003e\n  \u003cli\u003e3 - Model Organisms Used for Biomedical Research (p.289)\u003c\/li\u003e\n  \u003cli\u003e4 - The Nematode Caenorhabditis elegans: Small is Beautiful (p.290)\u003c\/li\u003e\n  \u003cli\u003e5 - The Basic Biology of Obesity: From a Worm’s Perspective (p.292)\u003c\/li\u003e\n  \u003cli\u003e6 - Key Features of Fat Metabolism in Caenorhabditis elegans (p.292)\u003c\/li\u003e\n  \u003cli\u003e7 - Technical Advances Driving Lipid Research in Nematodes (p.294)\u003c\/li\u003e\n  \u003cli\u003e8 - The Intestine: A Driver of Lipid Metabolism (p.295)\u003c\/li\u003e\n  \u003cli\u003e9 - The Lipid Droplets are the Main Site of Triglyceride Accumulation (p.295)\u003c\/li\u003e\n  \u003cli\u003e10 - The Nile Red Vital Staining Conundrum (p.296)\u003c\/li\u003e\n  \u003cli\u003e11 - Lysosome-Related Organelles Participate in Lipid Mobilization (p.296)\u003c\/li\u003e\n  \u003cli\u003e12 - Intestinal Autofluorescence: Friend or Foe? (p.297)\u003c\/li\u003e\n  \u003cli\u003e13 - A Whole Genome Approach (p.298)\u003c\/li\u003e\n  \u003cli\u003e14 - New Avenues of Label-Free Methods (p.298)\u003c\/li\u003e\n  \u003cli\u003e15 - Trends and Challenges (p.298)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.299)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.302)\u003c\/li\u003e\n  \u003cli\u003e2 - Thermogenesis—A Significant Determinant of Energy Expenditure (p.303)\u003c\/li\u003e\n  \u003cli\u003e3 - Concluding Remarks (p.325)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.325)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.334)\u003c\/li\u003e\n  \u003cli\u003e2 - Classical Models of Liver Fibrosis (p.335)\u003c\/li\u003e\n  \u003cli\u003e3 - Animal Models of Specific Liver Diseases (p.336)\u003c\/li\u003e\n  \u003cli\u003e4 Conclusions (p.354)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.354)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.364)\u003c\/li\u003e\n  \u003cli\u003e2 - Skin Healing in Lower Vertebrate (Anamniotes) Model Organisms (p.365)\u003c\/li\u003e\n  \u003cli\u003e3 - Skin Healing in Higher Vertebrate (Amniotes) Model Organisms (p.369)\u003c\/li\u003e\n  \u003cli\u003e4 - Genetic Mouse Models for Regenerative Skin Wound Healing (Transcription Factors in Skin Development and Regeneration) (p.371)\u003c\/li\u003e\n  \u003cli\u003e5 - Conclusions (p.374)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.374)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.378)\u003c\/li\u003e\n  \u003cli\u003e2 - Inflammatory Skin Disease Animal Models (p.380)\u003c\/li\u003e\n  \u003cli\u003e3 - Genetic Skin Disease Animal Models (p.387)\u003c\/li\u003e\n  \u003cli\u003e4 - Animal Models of Skin Cancer (p.388)\u003c\/li\u003e\n  \u003cli\u003e5 - Conclusions (p.391)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.392)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.400)\u003c\/li\u003e\n  \u003cli\u003e2 - Acute Kidney Disease (p.400)\u003c\/li\u003e\n  \u003cli\u003e3 - Chronic Kidney Disease: Animal Models (p.412)\u003c\/li\u003e\n  \u003cli\u003e4 - Conclusions (p.427)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.427)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.440)\u003c\/li\u003e\n  \u003cli\u003e2 - Rat Model (p.441)\u003c\/li\u003e\n  \u003cli\u003e3 - Mouse Model (p.446)\u003c\/li\u003e\n  \u003cli\u003e4 - Fly Model (p.449)\u003c\/li\u003e\n  \u003cli\u003e5 - Porcine Model (p.455)\u003c\/li\u003e\n  \u003cli\u003e6 - Other Animal Models (p.457)\u003c\/li\u003e\n  \u003cli\u003e7 - Canine Model (p.458)\u003c\/li\u003e\n  \u003cli\u003e8 - Feline Model (p.460)\u003c\/li\u003e\n  \u003cli\u003e9 - Conclusions (p.460)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.461)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.466)\u003c\/li\u003e\n  \u003cli\u003e2 - The Pig as Animal Model (p.467)\u003c\/li\u003e\n  \u003cli\u003e3 - The Sheep as Animal Model (p.474)\u003c\/li\u003e\n  \u003cli\u003e4 - The Rabbit as Animal Model (p.480)\u003c\/li\u003e\n  \u003cli\u003e5 - The Dog as Animal Model (p.482)\u003c\/li\u003e\n  \u003cli\u003e6 - Concluding Remarks (p.483)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.483)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.488)\u003c\/li\u003e\n  \u003cli\u003e2 - Historical Perspectives (p.489)\u003c\/li\u003e\n  \u003cli\u003e3 - Pathophysiology of IBD (p.489)\u003c\/li\u003e\n  \u003cli\u003e4 - Animal Models of Inflammatory Bowel Diseases (p.490)\u003c\/li\u003e\n  \u003cli\u003e5 - Conclusions (p.497)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.498)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.503)\u003c\/li\u003e\n  \u003cli\u003e2 - Systematic Review and Metaanalysis Method (p.503)\u003c\/li\u003e\n  \u003cli\u003e3 - Results (p.506)\u003c\/li\u003e\n  \u003cli\u003e4 - Discussion (p.532)\u003c\/li\u003e\n  \u003cli\u003e5 - Conclusions (p.538)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.539)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.546)\u003c\/li\u003e\n  \u003cli\u003e2 - Building Relevant Models (p.550)\u003c\/li\u003e\n  \u003cli\u003e3 - Olfactory–Neuromuscular Diseases (p.553)\u003c\/li\u003e\n  \u003cli\u003e4 - Conclusions (p.565)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.566)\u003c\/li\u003e\n  \u003cli\u003e1 - What is Substance Use Disorder and Why Should We Study It? (p.578)\u003c\/li\u003e\n  \u003cli\u003e2 - Reward and Reinforcement (p.579)\u003c\/li\u003e\n  \u003cli\u003e3 - Aversive Drug Effects (p.580)\u003c\/li\u003e\n  \u003cli\u003e4 - The Place Conditioning Procedure (p.581)\u003c\/li\u003e\n  \u003cli\u003e5 - The Flavor Conditioning Procedure (p.592)\u003c\/li\u003e\n  \u003cli\u003e6 - Conclusions (p.601)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.602)\u003c\/li\u003e\n  \u003cli\u003e1 - Overview of Schizophrenia (p.608)\u003c\/li\u003e\n  \u003cli\u003e2 - Approaches to Create Animal Models with Relevance to Schizophrenia (p.611)\u003c\/li\u003e\n  \u003cli\u003e3 - Features of Schizophrenia That can be Modeled in Animals (p.614)\u003c\/li\u003e\n  \u003cli\u003e4 - Specific Animal Models (p.621)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.631)\u003c\/li\u003e\n  \u003cli\u003e1 - Introductory Remarks (p.642)\u003c\/li\u003e\n  \u003cli\u003e2 - Klinefelter’s Syndrome—An Underestimated Disease (p.643)\u003c\/li\u003e\n  \u003cli\u003e3 - The X Chromosome in the Male (p.644)\u003c\/li\u003e\n  \u003cli\u003e4 - Clinical Features of Klinefelter’s Syndrome (p.646)\u003c\/li\u003e\n  \u003cli\u003e5 - Sex Chromosomal Aberrations in Male Mammals (p.648)\u003c\/li\u003e\n  \u003cli\u003e6 - Mouse Models for Klinefelter’s Syndrome (p.650)\u003c\/li\u003e\n  \u003cli\u003e7 - Lessons from Animal Experiments (p.652)\u003c\/li\u003e\n  \u003cli\u003e8 - Perspectives—What can be Expected From Future Animal Experiments and How to Retranslate Experimental Findings into Clin... (p.665)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.666)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.672)\u003c\/li\u003e\n  \u003cli\u003e2 - Zebrafish in the Laboratory: A Historical Overview (p.676)\u003c\/li\u003e\n  \u003cli\u003e3 - Forward Genetics: Phenotype-Driven Studies of Vertebrate Development (p.677)\u003c\/li\u003e\n  \u003cli\u003e4 - Reverse Genetics: Testing Candidate Genes in Zebrafish Models (p.678)\u003c\/li\u003e\n  \u003cli\u003e5 - Humanizing Zebrafish to Study Human Genetic Variation (p.681)\u003c\/li\u003e\n  \u003cli\u003e6 - Modeling Adult Onset Disease in Embryonic or Larval Stages (p.685)\u003c\/li\u003e\n  \u003cli\u003e7 - Therapeutic Discovery in Zebrafish Models of Disease (p.685)\u003c\/li\u003e\n  \u003cli\u003e8 - Conclusions: The Future of Zebrafish as a Human Genetic Disease Model (p.686)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.687)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.693)\u003c\/li\u003e\n  \u003cli\u003e2 - Techniques Used for the Generation of Genetically Engineered Pigs (p.694)\u003c\/li\u003e\n  \u003cli\u003e3 - Genetically Engineered Pigs as Models for Human Diseases (p.697)\u003c\/li\u003e\n  \u003cli\u003e4 - Conclusions (p.717)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.718)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.724)\u003c\/li\u003e\n  \u003cli\u003e2 - Some Historical Aspects (p.725)\u003c\/li\u003e\n  \u003cli\u003e3 - Techniques for the Creation of Genetically Modified Animals (p.725)\u003c\/li\u003e\n  \u003cli\u003e4 - Types of Genetically Modified Animals and how They are Produced (p.730)\u003c\/li\u003e\n  \u003cli\u003e5 - Genetically Modified Mice as Models of Human Diseases (p.732)\u003c\/li\u003e\n  \u003cli\u003e6 - Multifactorial and Polygenic (Complex) Disorders (p.732)\u003c\/li\u003e\n  \u003cli\u003e7 - Inflammatory Diseases (p.734)\u003c\/li\u003e\n  \u003cli\u003e8 - Neurodegenerative Diseases (p.734)\u003c\/li\u003e\n  \u003cli\u003e9 - Cancer (p.737)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.741)\u003c\/li\u003e\n  \u003cli\u003e1 - Genetic or Environmental (p.749)\u003c\/li\u003e\n  \u003cli\u003e2 - Genome Project and Human Diseases (p.749)\u003c\/li\u003e\n  \u003cli\u003e3 - Basic Genetics to Develop and Use Model Mice (p.750)\u003c\/li\u003e\n  \u003cli\u003e4 - Diploid and Genotype (p.751)\u003c\/li\u003e\n  \u003cli\u003e5 - Coisogenic and Congenic Strains (p.752)\u003c\/li\u003e\n  \u003cli\u003e6 - Double Stranded DNA, Linkage, and Haplotype (p.753)\u003c\/li\u003e\n  \u003cli\u003e7 - Mutant Mice as Disease Models (p.753)\u003c\/li\u003e\n  \u003cli\u003e8 - Fancy Mice (p.754)\u003c\/li\u003e\n  \u003cli\u003e9 - Laboratory Mouse Strains (p.754)\u003c\/li\u003e\n  \u003cli\u003e10 - Redundancy of Genes: Oculocutaneous Albinism (p.754)\u003c\/li\u003e\n  \u003cli\u003e11 - Body Weight and Brain Function: Pleiotropy of ob and db (p.755)\u003c\/li\u003e\n  \u003cli\u003e12 - Conventional Positional Cloning and Forward Genetics (p.755)\u003c\/li\u003e\n  \u003cli\u003e13 - Unique Positional Cloning: High Reversion Rates of dv and pun Mutations (p.756)\u003c\/li\u003e\n  \u003cli\u003e14 - Recombinant Inbred Strains for Quick Genetic Mapping (p.756)\u003c\/li\u003e\n  \u003cli\u003e15 - Mutagenesis for Forward Genetics (p.757)\u003c\/li\u003e\n  \u003cli\u003e16 - Large-Scale ENU Mouse Mutagenesis Project (p.759)\u003c\/li\u003e\n  \u003cli\u003e17 - Mutagenesis for Reverse Genetics (p.761)\u003c\/li\u003e\n  \u003cli\u003e18 - Gene Targeting and Knockout Mouse (p.761)\u003c\/li\u003e\n  \u003cli\u003e19 - Transgenic Mice as Disease Models (p.761)\u003c\/li\u003e\n  \u003cli\u003e20 - Knockout Mice as Disease Models (p.762)\u003c\/li\u003e\n  \u003cli\u003e21 - Conditional Targeting (p.762)\u003c\/li\u003e\n  \u003cli\u003e22 - International Knockout Mouse Consortium (p.762)\u003c\/li\u003e\n  \u003cli\u003e23 - ENU-Based Reverse Genetics in the Mouse (p.763)\u003c\/li\u003e\n  \u003cli\u003e24 - Further Advancement of Genome Technologies (p.764)\u003c\/li\u003e\n  \u003cli\u003e25 - Genome Editing Technologies (p.765)\u003c\/li\u003e\n  \u003cli\u003e26 - Concluding Remarks (p.767)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.768)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.776)\u003c\/li\u003e\n  \u003cli\u003e2 - Febrile Seizures in Humans and Their Relationship to Epilepsy (p.777)\u003c\/li\u003e\n  \u003cli\u003e3 - Animal Models of Febrile Seizures (Experimental Febrile Seizures) (p.778)\u003c\/li\u003e\n  \u003cli\u003e4 - Other Animal Models of Early Life Seizures (p.780)\u003c\/li\u003e\n  \u003cli\u003e5 - Mechanisms Underlying Hyperthermia-Induced Experimental Febrile Seizures (p.780)\u003c\/li\u003e\n  \u003cli\u003e6 - Neuroanatomical Changes After Experimental Febrile Seizures (p.782)\u003c\/li\u003e\n  \u003cli\u003e7 - Neurophysiological Changes After Experimental Febrile Seizures (p.784)\u003c\/li\u003e\n  \u003cli\u003e8 - Neuronal Hyperactivity After Experimental Febrile Seizures (p.785)\u003c\/li\u003e\n  \u003cli\u003e9 - Behavioral Changes After Experimental Febrile Seizures (p.785)\u003c\/li\u003e\n  \u003cli\u003e10 - Conclusions (p.786)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.786)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.790)\u003c\/li\u003e\n  \u003cli\u003e2 - Infection, Inflammation, and Preterm Birth (p.792)\u003c\/li\u003e\n  \u003cli\u003e3 - Innate Immune Responses (p.795)\u003c\/li\u003e\n  \u003cli\u003e4 - Inflammation and Labor (p.797)\u003c\/li\u003e\n  \u003cli\u003e5 - The Use of Animals in the Study of Preterm Birth—Justification and Validity (p.798)\u003c\/li\u003e\n  \u003cli\u003e6 - Animal Models of Infection-Associated Inflammation (p.799)\u003c\/li\u003e\n  \u003cli\u003e7 - Summary (p.805)\u003c\/li\u003e\n  \u003cli\u003e8 - Practical Study—Fetal Surgery in the Sheep (p.805)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.819)\u003c\/li\u003e\n  \u003cli\u003e1 - Establishment of Air Breathing at Birth (p.827)\u003c\/li\u003e\n  \u003cli\u003e2 - Neonatal Lung Diseases (p.832)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.835)\u003c\/li\u003e\n  \u003cli\u003e2 - Normal Physiological Course of Ductus Arteriosus (p.836)\u003c\/li\u003e\n  \u003cli\u003e3 - Pathophysiology of Patent Ductus Arteriosus (p.836)\u003c\/li\u003e\n  \u003cli\u003e4 - Treatment for Patent Ductus Arteriosus (p.836)\u003c\/li\u003e\n  \u003cli\u003e5 - Animal Models of Patent Ductus Arteriosus (p.836)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.837)\u003c\/li\u003e\n  \u003cli\u003e2 - Normal Vascularization of Human Retina (p.837)\u003c\/li\u003e\n  \u003cli\u003e3 - Pathophysiology of Retinopathy of Prematurity (p.838)\u003c\/li\u003e\n  \u003cli\u003e4 - Treatment of Retinopathy of Prematurity (p.838)\u003c\/li\u003e\n  \u003cli\u003e5 - Animal Models of Retinopathy of Prematurity (p.838)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.840)\u003c\/li\u003e\n  \u003cli\u003e2 - Pathophysiology of Intraventricular Hemorrhage (p.840)\u003c\/li\u003e\n  \u003cli\u003e3 - Prevention of Intraventricular Hemorrhage (p.841)\u003c\/li\u003e\n  \u003cli\u003e4 - Animal Models of Intraventricular Hemorrhage (p.841)\u003c\/li\u003e\n  \u003cli\u003e1 - Epidemiology, Etiology, and Animal Models (p.842)\u003c\/li\u003e\n  \u003cli\u003e2 - Fetal Inflammation (p.842)\u003c\/li\u003e\n  \u003cli\u003e3 - Fetal Acidemia (p.843)\u003c\/li\u003e\n  \u003cli\u003e1 - Etiology (p.844)\u003c\/li\u003e\n  \u003cli\u003e2 - Chorioamnionitis: Pathological Fetal Inflammation Is a Risk Factor (p.844)\u003c\/li\u003e\n  \u003cli\u003e3 - Tight Junctions: Intestinal Permeability and Integrity (p.845)\u003c\/li\u003e\n  \u003cli\u003e4 - Intestinal Permeability Is Influenced by Pathogens and Inflammation (p.845)\u003c\/li\u003e\n  \u003cli\u003e5 - ENS Controls Epithelial Barrier Function (p.845)\u003c\/li\u003e\n  \u003cli\u003e6 - NEC: Immature Immune Response (p.846)\u003c\/li\u003e\n  \u003cli\u003e7 - Development and Monitoring of the Autonomic Nervous System Activity (p.846)\u003c\/li\u003e\n  \u003cli\u003e8 - CAP Controls Immune Homeostasis (p.846)\u003c\/li\u003e\n  \u003cli\u003e9 - Vagal Nerve Stimulation and the Gut Inflammation (p.847)\u003c\/li\u003e\n  \u003cli\u003e10 - Near Future: Early Detection of NEC Using Fetal and Neonatal Heart Rate Monitoring? (p.848)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.848)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.860)\u003c\/li\u003e\n  \u003cli\u003e2 - Significance (p.862)\u003c\/li\u003e\n  \u003cli\u003e3 - Preclinical Studies of Prenatal Stress in Rodent Models (p.863)\u003c\/li\u003e\n  \u003cli\u003e4 - Experimental Paradigm for a Trans- and Multigenerational PS Rat Model (p.866)\u003c\/li\u003e\n  \u003cli\u003e5 - Large Animal Models of Fetal Development to Model PS: Pregnant Sheep (p.866)\u003c\/li\u003e\n  \u003cli\u003e6 - Experimental Paradigm for Prenatal Stress Model in Fetal Sheep (p.867)\u003c\/li\u003e\n  \u003cli\u003e7 - Conclusions (p.867)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.867)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.874)\u003c\/li\u003e\n  \u003cli\u003e2 - Caliciviridae (p.875)\u003c\/li\u003e\n  \u003cli\u003e3 - Togaviridae (p.876)\u003c\/li\u003e\n  \u003cli\u003e4 - Flaviviridae (p.879)\u003c\/li\u003e\n  \u003cli\u003e5 - Coronaviridae (p.882)\u003c\/li\u003e\n  \u003cli\u003e6 - Filoviridae (p.885)\u003c\/li\u003e\n  \u003cli\u003e7 - Orthomyxoviridae (p.891)\u003c\/li\u003e\n  \u003cli\u003e8 - Bunyaviridae (p.894)\u003c\/li\u003e\n  \u003cli\u003e9 - Arenaviridae (p.897)\u003c\/li\u003e\n  \u003cli\u003e10 - Retroviridae (p.898)\u003c\/li\u003e\n  \u003cli\u003e11 - Papillomaviridae (p.900)\u003c\/li\u003e\n  \u003cli\u003e12 - Poxviridae (p.901)\u003c\/li\u003e\n  \u003cli\u003e13 - Hepadnaviridae (p.904)\u003c\/li\u003e\n  \u003cli\u003e14 - Conclusions (p.905)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.906)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.926)\u003c\/li\u003e\n  \u003cli\u003e2 - Generation of CRISPR Cancer Models (p.932)\u003c\/li\u003e\n  \u003cli\u003e3 - Challenges and Solutions (p.938)\u003c\/li\u003e\n  \u003cli\u003e4 - Concluding Remarks (p.940)\u003c\/li\u003e\n  \u003cli\u003eGlossary (p.940)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.941)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction to Animal Models of Breast Cancer (p.947)\u003c\/li\u003e\n  \u003cli\u003e2 - Concepts of Breast Cancer Biology (p.947)\u003c\/li\u003e\n  \u003cli\u003e3 - Modeling Breast Cancer in Rodents (p.949)\u003c\/li\u003e\n  \u003cli\u003e4 - Spontaneous and Induced Mammary Tumorigenesis in Rodents (p.949)\u003c\/li\u003e\n  \u003cli\u003e5 - Grafting and Transplantation Approaches (p.953)\u003c\/li\u003e\n  \u003cli\u003e6 - Genetically Engineered Mouse Models of Breast Cancer (p.961)\u003c\/li\u003e\n  \u003cli\u003e7 - Comparative Pathology and Genomics: Mouse Mammary Tumors Versus Human Breast Cancer (p.963)\u003c\/li\u003e\n  \u003cli\u003e8 - Studying Metastasis in Mice With an Emphasis on New Models (p.964)\u003c\/li\u003e\n  \u003cli\u003e9 - Emerging Nonrodent Models of Breast Cancer (p.965)\u003c\/li\u003e\n  \u003cli\u003e10 - Conclusions (p.965)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.966)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.972)\u003c\/li\u003e\n  \u003cli\u003e2 - Bleomycin-Induced Murine Scleroderma (p.973)\u003c\/li\u003e\n  \u003cli\u003e3 - HOCl-Induced Murine Scleroderma (p.978)\u003c\/li\u003e\n  \u003cli\u003e4 - Tight Skin Mouse (p.978)\u003c\/li\u003e\n  \u003cli\u003e5 - Sclerodermatous Graft-Versus-Host Disease Model (p.980)\u003c\/li\u003e\n  \u003cli\u003e6 - Skin Fibrosis by Exogenous Injection of Growth Factors (p.980)\u003c\/li\u003e\n  \u003cli\u003e7 - UCD-200 Chicken (p.981)\u003c\/li\u003e\n  \u003cli\u003e8 - Transgenic Mouse Models (p.981)\u003c\/li\u003e\n  \u003cli\u003e9 - Knockout Mouse Models (p.981)\u003c\/li\u003e\n  \u003cli\u003e10 - Conclusions (p.982)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.982)\u003c\/li\u003e\n  \u003cli\u003e1 - The Complex Biology of Multiple Sclerosis (p.988)\u003c\/li\u003e\n  \u003cli\u003e2 - Immunological Models for CNS Demyelination (p.992)\u003c\/li\u003e\n  \u003cli\u003e3 - Local Induction of Demyelination Following Injection of Myelin Peptides (p.994)\u003c\/li\u003e\n  \u003cli\u003e4 - Development of MS Therapies Based on Models of Immune Mediated Demyelinating Diseases (p.995)\u003c\/li\u003e\n  \u003cli\u003e5 - Viral mediated Models of Demyelination (p.995)\u003c\/li\u003e\n  \u003cli\u003e6 - Oligodendrocyte Induced Cell Death Models of Demyelination (p.996)\u003c\/li\u003e\n  \u003cli\u003e7 - Toxin Models of Demyelination (p.1000)\u003c\/li\u003e\n  \u003cli\u003e8 - Conclusions and Comments (p.1005)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1005)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.1012)\u003c\/li\u003e\n  \u003cli\u003e2 - Animal Models of Major Depression (p.1013)\u003c\/li\u003e\n  \u003cli\u003e3 - Animal Models of Mania (p.1018)\u003c\/li\u003e\n  \u003cli\u003e4 - Conclusions (p.1021)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1021)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.1024)\u003c\/li\u003e\n  \u003cli\u003e2 - Operant Tasks for Testing Cognitive Functioning (p.1025)\u003c\/li\u003e\n  \u003cli\u003e3 - Nonoperant Behavioral Tests (p.1032)\u003c\/li\u003e\n  \u003cli\u003e4 - Welfare Aspects in the Use of Pigs as Model Species (p.1040)\u003c\/li\u003e\n  \u003cli\u003e5 - Conclusions (p.1045)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1045)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.1052)\u003c\/li\u003e\n  \u003cli\u003e2 - Invertebrate Models of Alzheimer’s Disease (p.1053)\u003c\/li\u003e\n  \u003cli\u003e3 - Nonmammalian Vertebrate Models of Alzheimer’s Disease (p.1062)\u003c\/li\u003e\n  \u003cli\u003e4 - Mammalian Models of Alzheimer’s Disease (p.1072)\u003c\/li\u003e\n  \u003cli\u003e5 - Conclusions (p.1087)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1087)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.1109)\u003c\/li\u003e\n  \u003cli\u003e2 - Clinical Characteristics of PD and Their Relevant Symptoms in Animal Models (p.1112)\u003c\/li\u003e\n  \u003cli\u003e3 - Molecular Pathophysiology of PD (p.1113)\u003c\/li\u003e\n  \u003cli\u003e4 - Neurotoxins for Making PD Models (p.1114)\u003c\/li\u003e\n  \u003cli\u003e5 - MPTP-Induced Mice Model of PD (p.1116)\u003c\/li\u003e\n  \u003cli\u003e6 - MPTP-Induced Common Marmoset Model for PD (p.1122)\u003c\/li\u003e\n  \u003cli\u003e7 - Concluding Remarks (p.1125)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1125)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.1130)\u003c\/li\u003e\n  \u003cli\u003e2 - Parkinson’s Disease (p.1131)\u003c\/li\u003e\n  \u003cli\u003e3 - Alzheimer’s Disease (p.1134)\u003c\/li\u003e\n  \u003cli\u003e4 - Huntington’s Disease (p.1136)\u003c\/li\u003e\n  \u003cli\u003e5 - Amyotrophic Lateral Sclerosis (p.1138)\u003c\/li\u003e\n  \u003cli\u003e6 - Frontotemporal Dementia (p.1140)\u003c\/li\u003e\n  \u003cli\u003e7 - Conclusions (p.1142)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1145)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.1152)\u003c\/li\u003e\n  \u003cli\u003e2 - Insights From Pharmacological Animal Models of Mania (p.1153)\u003c\/li\u003e\n  \u003cli\u003e3 - Insights From Environmental Models (p.1158)\u003c\/li\u003e\n  \u003cli\u003e4 - Insights From Genetic Models (p.1159)\u003c\/li\u003e\n  \u003cli\u003e5 - Conclusions (p.1159)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1160)\u003c\/li\u003e\n  \u003cli\u003e1 - Introduction (p.1166)\u003c\/li\u003e\n  \u003cli\u003e2 - Learning to Cope Training (p.1167)\u003c\/li\u003e\n  \u003cli\u003e3 - Learning to Cope Is Stressful (p.1167)\u003c\/li\u003e\n  \u003cli\u003e4 - Learning to Cope Reduces Subsequent Behavioral Measures of Emotionality (p.1168)\u003c\/li\u003e\n  \u003cli\u003e5 - Learning to Cope Increases Anterior Cingulate Cortex Stargazin Gene Expression (p.1169)\u003c\/li\u003e\n  \u003cli\u003e6 - Discussion (p.1170)\u003c\/li\u003e\n  \u003cli\u003e7 - Limitations (p.1172)\u003c\/li\u003e\n  \u003cli\u003e8 - Conclusions (p.1172)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1172)\u003c\/li\u003e\n  \u003cli\u003eIndex (p.1176)\u003c\/li\u003e\n  \u003cli\u003e\u003cem\u003e... and 157 more chapters\u003c\/em\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cdiv style=\"margin:20px 0;\"\u003e\n\u003ch3\u003ePreview This Book (First 20 Pages)\u003c\/h3\u003e\n\n\u003cp style=\"font-size:12px;color:#666;margin-top:4px;\"\u003eScroll through the preview above to see the first 20 pages of this book.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e🔗 Download Link:\u003c\/strong\u003e \u003c\/p\u003e","brand":"Global Vet \u0026 Co","offers":[{"title":"Default Title","offer_id":51226932216123,"sku":null,"price":210.0,"currency_code":"HKD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0948\/3062\/5083\/files\/diagnosis-and-treatment-of-joint-disease-of-small-animals_HD.png?v=1780504711","url":"https:\/\/globalvetco.com\/products\/diagnosis-and-treatment-of-joint-disease-of-small-animals","provider":"Global Vet \u0026 Co Ltd","version":"1.0","type":"link"}